NB S101

NB S101, the lead compound of Osteologix, has a demonstrated ability to decrease resorption of bone while maintaining or increasing formation of new bone. This combined mechanism of action sets it aside from existing therapies in osteoporosis which are primarily only anti-resorptive.
Osteologix has completed an extensive preclinical program demonstrating the pharmacodynamic effects of NB S101 as well as documenting its safety and toxicological properties.
The clinical areas being investigated all comprise disorders where bone and cartilage metabolism is affected, including osteoporosis, osteoarthritis, metastatic bone disease, hyperparathyroidism-associated bone disease, secondary osteoporosis and renal disease.

NB S101 is a novel dual acting bone agent that can significantly improve bone density and reduce fracture risk. In preclinical models of osteoporosis, NB S101 has demonstrated beneficial effects on both reducing bone resorption and increasing high quality strong bone formation and bone mineralization. This dual action on bone– a significant medical need that is not served by current treatments – suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis.
NB S101, is currently in phase II clinical trials.